First slide

The leading pharmaceutical company Mylan N.V signed an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited’s thrombosis business in Europe for approximately $754 million.

  • The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names, and variations of the brand names, Arixtra, Fraxiparine, Mono-Embolex and Orgaran.

In May 2020, Mylan N.V announced, as part of its ongoing efforts to support patients and public health needs during the COVID-19 pandemic, a global collaboration with Gilead Sciences to expand access to the investigational antiviral remdesivir for the potential treatment of COVID-19.

In April 2020, Mylan N.V. and Biocon Ltd. announced the launch of Fulphila, a biosimilar to Neulasta¬ģ (pegfilgrastim). Fulphila is approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.

In Nov 2019, Mylan N.V. and Pfizer Inc. announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘vi?-tr?s).

About Mylan
Mylan, headquartered in Canonsburg, Pennsylvania, United States, is a leading pharmaceutical company. The company offers a portfolio of more than 7,500 marketed products globally, including antiretroviral therapies on which approximately 40% of people being treated for HIV/AIDS globally depend. The company’s products are available in more than 165 countries and territories. The company has a workforce of approximately 35,000 people across the globe.

Prominent Global Investors

View all

Related News